Carlisle Companies Incorporated (CSL)

Debt-to-equity ratio

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Long-term debt US$ in thousands
Total stockholders’ equity US$ in thousands 2,463,300 2,762,900 3,004,300 2,859,300 2,829,000 2,923,800 3,032,000 3,058,300 3,024,400 3,041,700 2,875,100 2,678,600 2,629,500 2,544,800 2,417,900 2,411,800 2,537,700 2,475,300 2,516,200 2,518,500
Debt-to-equity ratio 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

December 31, 2024 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $2,463,300K
= 0.00

The debt-to-equity ratio for Carlisle Companies Incorporated has consistently been reported as 0.00 throughout the time periods provided, from March 31, 2020, to December 31, 2024. This indicates that the company has had no debt in relation to its equity during these periods. A debt-to-equity ratio of 0.00 suggests that the company is primarily financed by equity rather than debt. This can be viewed positively as it signifies lower financial risk and potential stability in the company's financial structure. However, it's important to note that a very low or zero debt-to-equity ratio could also indicate missed opportunities for leveraging debt to potentially enhance returns for shareholders. Overall, maintaining a consistent debt-to-equity ratio of 0.00 reflects Carlisle Companies' conservative financial approach and strong equity base.


Peer comparison

Dec 31, 2024

Company name
Symbol
Debt-to-equity ratio
Carlisle Companies Incorporated
CSL
0.00
West Pharmaceutical Services Inc
WST
0.00